Trending...
- Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match
- LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement
- Spokane Police is Seeking Assistance Locating a Missing Adult Male
SEATTLE ~ Seattle, WA - Tasso, Inc., a leading provider of patient-centric blood collection solutions, has announced the launch of their new service, Tasso Care® for Prescreening. This end-to-end solution aims to improve the success of prescreening programs by expanding on the company's expertise in remote blood collection and analysis.
Tasso Care for Prescreening is specifically designed to support the prescreening of participants in clinical trials for various cardiometabolic and serostatus markers. The company plans to add additional panels for immunology, cardiovascular disease, and other therapeutic areas throughout the first quarter of 2024 as validation protocols are completed.
According to Tasso CEO and Co-Founder Ben Casavant, PhD, screening participants is a major bottleneck in drug development that often leads to trial delays and high screen failure rates. With Tasso Care, this process is revolutionized by replacing time-consuming clinic visits with convenient and automated prescreening testing at scale.
More on Washingtoner
By offering a virtually painless blood draw experience from the comfort of home, Tasso aims to increase clinical trial engagement rates by simplifying the operational process and optimizing the participants' experience. This also ensures a high-quality sample is returned to the lab. Additionally, Tasso Care allows for large populations to be screened simultaneously anytime and anywhere, ultimately increasing trial access and diversity.
Casavant believes that accelerating and expanding access to clinical trials is crucial in improving healthcare. He states that trials often face enrollment delays due to difficulties in identifying rare populations and obtaining up-to-date data. With Tasso Care for Prescreening, these challenges can be overcome as screening becomes more scalable and convenient.
It should be noted that Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about this new service from Tasso Inc., please visit their website at www.tassoinc.com/prescreening.
Tasso Care for Prescreening is specifically designed to support the prescreening of participants in clinical trials for various cardiometabolic and serostatus markers. The company plans to add additional panels for immunology, cardiovascular disease, and other therapeutic areas throughout the first quarter of 2024 as validation protocols are completed.
According to Tasso CEO and Co-Founder Ben Casavant, PhD, screening participants is a major bottleneck in drug development that often leads to trial delays and high screen failure rates. With Tasso Care, this process is revolutionized by replacing time-consuming clinic visits with convenient and automated prescreening testing at scale.
More on Washingtoner
- Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
- Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Proform Builds Releases Short Documentary on Founder Joey Fentress and the Story Behind the Company
By offering a virtually painless blood draw experience from the comfort of home, Tasso aims to increase clinical trial engagement rates by simplifying the operational process and optimizing the participants' experience. This also ensures a high-quality sample is returned to the lab. Additionally, Tasso Care allows for large populations to be screened simultaneously anytime and anywhere, ultimately increasing trial access and diversity.
Casavant believes that accelerating and expanding access to clinical trials is crucial in improving healthcare. He states that trials often face enrollment delays due to difficulties in identifying rare populations and obtaining up-to-date data. With Tasso Care for Prescreening, these challenges can be overcome as screening becomes more scalable and convenient.
It should be noted that Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about this new service from Tasso Inc., please visit their website at www.tassoinc.com/prescreening.
0 Comments
Latest on Washingtoner
- Extreme Lead Program Highlights $27 Real Human Traffic Test for Affiliate and Network Marketers
- Call 311 for Non-Emergency Help in City of Spokane Limits
- Paraguay Expedition Offers a Different View of Human Resilience
- Longevity Academy Features Gail Humble, MD of KLOTHO SKIN in the Longevity Leaders Project
- Datavalet Named One of Quebec's Best Workplaces™ for 2026
- Phinge Corporation Engages Sheridan Ross PC for Certain Intellectual Property Matters
- Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
- Slotozilla Hosts Exclusive Halloween Casino Bonuses for 2026
- Remcon Equipment Marks 35 Years as a Conveyor Company, With 1,500+ Systems Built
- "BROOKLYN, BROOKLYN, BROOKLYN" children's book and official YouTube channel launch on October 27th
- Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
- Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
- Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)
- EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
- With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
- We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery
- One in three Americans may have lost track of retirement savings from a previous job
- Political Concerns Drive US Investors to Golden Visas
- Tacoma: T-Town Takes Over the Dome Oct. 30